ARTHUR-D.-LITTLE
18.11.2021 12:44:05 CET | Business Wire | Press release
Arthur D. Little (ADL) today released ‘The insight: how Europe’s private equity industry is anchoring long-term investors’, a new report based on a survey conducted in partnership with Invest Europe, the association that represents Europe’s private equity, venture capital and infrastructure sectors and their investors. The report shows that, despite the ongoing impact of COVID-19 on business and society, private equity investment levels reached a new record high in the first half of 2021. This is a dramatic bounce-back compared to the same period last year, with fund managers and investors evidently facing the future with greater confidence.
The report also highlights that far from adopting a return to ‘business as usual’ approach, private equity is now concentrating on new priorities, with the greatest shift being an increased focus on environmental, social and governance (ESG) issues. For example, 95.5% of general partners (GPs) said they intended to increase their focus on ESG over the coming year, and 86% are planning to concentrate more on diversity and inclusion. In addition, 45.9% of investors expecting to increase allocations to environmental/social impact funds over the coming 12 months.
While cost reduction was the top prioritized initiative for GPs last year, it dropped to sixth place in this year’s survey. Instead, the leading priority was digitalization as managers invest in technology to add value. In particular, the pandemic has spurred a mass roll-out of new technology solutions at portfolio companies to enable flexible ways of working for staff and build more innovative platforms for improved collaboration.
As the general outlook improves, the survey indicates a healthy future for private equity. More than 50% of fund managers see stronger investment opportunities in the coming year, and almost 60% of investors expect increased allocations to private equity over the coming three years.
Jonas Fagerlund, co-author of the report and Lead Partner in ADL’s Global Private Equity practice , comments: “The message that comes through loud and clear through this report and the survey it is based on is that European private equity is adaptable, resilient and innovative, and looking forward to the future. The industry has come through a challenging period for the global economy with higher-than-ever levels of investment, robust fundraising, and an improving outlook for divestments.”
Guillaume Picq, co-author of the report and Partner in ADL’s Private Equity practice , adds, “While GPs are looking to deploy new value creation strategies, more investors want to commit to funds that deliver tangible benefits for people and the planet alongside investment returns. ESG is a trend that Europe is leading, and that the European private equity industry is committed to supporting.”
To download a copy of the report please visit: www.adl.com/PrivateEquityAnchor
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118005726/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
